This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=105 http://www.lsis.com/goto/r105/rss 2012-02-05T11:11:07+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 An efficient and high-yielding cross-coupling reaction of various primary, secondary, and tertiary alkyl chlorides with aryl Grignard reagents was achieved by using catalytic amounts of N-heterocyclic carbene ligands and iron salts. This reaction is a simple and efficient arylation method having applicability to a wide range of industrially abundant chloroalkanes, including polychloroalkanes, which are challenging substrates under conventional cross-coupling conditions. |-| Org Lett. |-| (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 Astrocytes associated with beta-amyloid (A?)-deposited senile plaques are a common neuropathological feature of Alzheimer's disease (AD). There is little doubt that the association of A? with the major component in the central nervous system cells significantly influences disease progression, however, the molecular mechanisms by which A? contributes to the astrocyte-mediated neuropathological changes have not been well established. In an effort to identify astrocyte-derived molecules that (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=105 Daiichi Sankyo Co. said on Tuesday it fell into the red for the fiscal third quarter and further lowered its full-year outlook, hurt again by the stubbornly strong yen and legal costs associated with its Indian unit. The Japanese firm acquired a little more than 60% of Indian generic drugmaker Ranbaxy Laboratories Ltd. for $4.6 billion in 2008. But U.S. government allegations of improper manufacturing practices and data falsification have prevented the company from fully benefiting from the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 S1P(3)-sparing S1P(1) agonists have attracted attention as a suppressant of autoimmunity with reduced side effects. Our synthetic efforts and extensive SAR studies led to the discovery of 10b named CS-2100 with the EC(50) value of 4.0nM for human S1P(1) and over 5000-fold selectivity against S1P(3). The in vivo immunosuppressive efficacy was evaluated in rats on host versus graft reaction and the ID(50) value was determined at 0.407mg/kg. The docking studies of CS-2100 with the homology model (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 Multiple whitish nodules in the thoracic cavity at the site of the thymus were observed in a 101-week-old male ICR mouse. In a histopathological examination, the neoplastic cells were predominantly fusiform in shape and proliferated in sarcomatoid growth patterns. Some neoplastic cells showed epithelial growth patterns, such as the ductal structures. Mitotic figures were frequently seen, and small necrotic foci and invasion to adjacent thoracic organs were noted. In Alcian blue staining, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 For the purpose of obtaining orally potent VLA-4 inhibitors, we have carried out structural modification of the (N'-phenylureido)phenyl group in compound 1, where the group was found to be attributed to poor pharmacokinetic profile in our previous research. Through modification, we have identified several compounds with both potent in vitro activity and improved oral exposure. In particular, compound 7e with 7-fluoro-2-(1-methyl-1H-indol-3-yl)-1,3-benzoxazolyl group as a novel replacement of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 Toxicogenomics (TGx) is a widely used technique in the preclinical stage of drug development to investigate the molecular mechanisms of toxicity. A number of candidate TGx biomarkers have now been identified and are utilized for both assessing and predicting toxicities. Further accumulation of novel TGx biomarkers will lead to more efficient, appropriate and cost effective drug risk assessment, reinforcing the paradigm of the conventional toxicology system with a more profound understanding of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=105 GURGAON, India-(BUSINESS WIRE)- Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) ( œRanbaxy ) today announced that the consent decree with the U.S. Food and Drug Administration ( œFDA ) that was signed on December 20, 2011 has been filed with the United States District Court for the District of Maryland. Under the terms of the consent decree, which is subject to approval by this Court, Ranbaxy has committed to further strengthen procedures and policies to ensure data (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=105 United States Patent: 8101650 |-| Title: Method for treating a immunology-related disease |-| Inventors: Nishi; Takahide (Tokyo, JP), Shimozato; Takaichi (Miura, JP), Nara; Futoshi (Yachiyo, JP), Miyazaki; Shojiro (Tokyo, JP) |-| Assignee: Daiichi Sankyo Company, Limited (Tokyo, JP) |-| A method for treating an immunology-related disease. The method involves administering to a mammal in need thereof a pharmaceutically effective amount of an amino acid compound, a pharmacologically acceptable (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=105 Daiichi Sankyo, the Japanese owner of Ranbaxy Laboratories, has deputed two executives to monitor the Indian drug maker's new plant that will be the main source for supplying medicines for the US market. A person aware of the development said these two executives, who are at the general manager and director level, would be based at the company's new facility at Mohali, Punjab, which was approved by the US Food and Drug Administration (FDA) last month. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 Atrial fibrillation (AF) is the most common arrhythmia encountered by generalists and cardiologists alike. Much of the attendant morbidity from AF arises from systemic embolic complications which are effectively reduced with utilization of anti-platelet and/or anticoagulant therapy. The systemic embolic complications of AF and the medical therapy to attenuate these risks are very well established. Through the course of this review, we aim to highlight the complex relationship between AF and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=105 WOBURN, Mass.-(BUSINESS WIRE)-ArQule, Inc. (NASDAQ: ARQL) today announced that treatment with tivantinib as single agent therapy produced a statistically significant 56 percent improvement in time-to-progression (TTP) in the intent-to-treat (ITT) population, the primary endpoint in a randomized, controlled Phase 2 clinical trial in previously treated patients with hepatocellular carcinoma (HCC) (hazard ratio = 0.64; log rank p-value = 0.04). Adverse events were reported at similar rates in (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=105 United States Patent: 8097622 |-| Title: Morpholinopurine derivatives |-| Inventors: Nakayama; Kiyoshi (Chiba, JP), Sugita; Kazuyuki (Tokyo, JP), Setoguchi; Masaki (Tokyo, JP), Tominaga; Yuichi (Tokyo, JP), Saitou; Masanori (Tokyo, JP), Odagiri; Takashi (Kanagawa, JP) |-| Assignee: Daiichi Sankyo Company, Limited (Chuo-ku, JP) |-| There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 We identified four degradants (Dg-A, Dg-B, Dg-C, Dg-D) of azelnidipine to be generated under radical initiator-based oxidative conditions and proposed the mechanistic pathway for their formation. 2,2'-Azobisisobutyronitrile was used as a radical initiator. There appeared to be two major pathways in the oxidation of the 1,4-dihydropyridine moiety. One was initiated by hydrogen abstraction from the C-4 position of the dihydropyridine ring, followed by hydrogen abstraction from the N-1 position, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 Peroxisome proliferator-activated receptor gamma (PPAR?) is a potential drug target for treating type 2 diabetes. The selective PPAR? modulators (SPPARMs), which partially activate the PPAR? transcriptional activity, are considered to improve the plasma glucose level with attenuated PPAR? related adverse effects. However, the relationships between desired pharmacological profiles and ligand specific PPAR? transcriptional profiles have been unclear. And there is also little knowledge of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 Sitafloxacin (STFX) hydrate is a non-stoichiometric hydrate. The hydration state of STFX hydrate varies non-stoichiometrically depending on the relative humidity and temperature, though X-ray powder diffraction (XRPD) of STFX hydrate was not affected by storing at low and high relative humidities. The detailed properties of crystalline water of STFX hydrate were estimated in terms of hygroscopicity, thermal analysis combined with X-ray powder diffractometry, crystallography and density (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 A small series of piperidine analogs that effectively activate glycogen synthase (GS) was prepared in WO2011058122. The treatment or prophylaxis of metabolic disease and disorders by these novel GS activators is claimed. These compounds represent further variations around a structural motif explored in the prior patent publications by Roche. |-| Expert Opin Ther Pat. |-| Uto Y. |-| Daiichi Sankyo Co., Ltd, Lead Discovery & Optimization Research Laboratories I , 1-2-58, Hiromachi, (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=105 United States Patent: 8088796 |-| Title: Triamine derivative |-| Inventors: Mochizuki; Akiyoshi (Edogawa-ku, JP), Nagata; Tsutomu (Edogawa-ku, JP) |-| Assignee: Daiichi Sankyo Company, Limited (Tokyo, JP) |-| An object of the present invention is to provide a novel compound which has a potent inhibitory effect on FXa and exhibits an excellent antithrombotic effect when orally administered. The present invention provides a compound represented by the following general formula (1): #STR00001# (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 Modeling and simulation were used extensively in the development of an indication for the use of olmesartan medoxomil in pediatric patients with hypertension. Simulations based on models developed in adult patients indicated that two dose groups were sufficient to estimate a dose-response relationship, thereby reducing by one-third the number of subjects required for the phase III pediatric study. Model-based predictions for blood pressure reduction agreed with the observed results of the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 Edoxaban, an oral, direct factor Xa inhibitor, has a similar or low incidence of bleeding events compared with other anticoagulants in clinical trials. Therefore, agents to reverse the anticoagulant effects of edoxaban could be desirable in emergency situations. In this study, the reversal effects of haemostatic agents were determined on prothrombin time (PT) prolongation in vitro and bleeding time prolongation in vivo by edoxaban. PT using human plasma was measured in the presence of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 The oxidative conversion of silyl enol ethers to ?,?-unsaturated ketones using a less-hindered class of oxoammonium salts (AZADO(+)BF(4)(-) is described. The reaction proceeds via the ene-like addition of oxoammonium salts to silyl enol ethers. |-| Org Lett. |-| Hayashi M, Shibuya M, Iwabuchi Y. |-| Department of Organic Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aobayama, Sendai 980-8578, Japan, and Process Technology Research Laboratories, Daiichi Sankyo (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 We investigated the impact of glutathione S-transferases Mu 1 (GSTM1)- and Theta 1 (GSTT1)-null genotypes on hepatic GST activities in humans, and compared the results with those of Gstm1- and Gstt1-null mice. In liver with GSTM1/Gstm1-null genotype, GST activity toward p-nitrobenzyl chloride (NBC) was significantly decreased in both humans and mice. Additionally, in liver with GSTT1/Gstt1-null genotype, GST activity toward dichloromethane (DCM) was significantly decreased in both humans and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=105 Top 10: 2011 in Review Here it is, our fourth annual Top 10 Year in Review-a wholly subjective look at the 10 stories or trends that shaped the year in biotech. Drum roll, please. #10 Bad PR. FDA has made an effort to get unapproved drugs off the market by offering incentives to the companies that choose to jump through the proper hoops and get formal approvals. That's just what K-V Pharmaceuticals did for hydroxyprogesterone caproate, a drug used to prevent preterm labor. And it duly hiked (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=105 BERKELEY, Calif.-(BUSINESS WIRE)-Plexxikon Inc., a member of Daiichi Sankyo Group, today announced scientific findings from preclinical studies showing that treatment with a novel oral agent, PLX3397, selectively inhibited key cancer-driving Flt3 mutations that occur in 20-30 percent of acute myeloid leukemia (AML) patients. In a preclinical model of AML, PLX3397 showed significant tumor regression. This preclinical work also showed that PLX3397 retained activity against certain (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 We have previously reported that human total body clearance (CL) and steady-state volume of distribution (Vss) of monoclonal antibodies (mAbs) could be predicted reasonably well from monkey data alone using simple allometry with scaling exponents of 0.79 and 1.12 (for soluble targets), and 0.96 and 1.00 (for membrane-bound targets), respectively. In the present study, to predict the plasma concentration-time profiles of mAbs in humans, we employed simple dose-normalization and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 J Clin Hypertens (Greenwich). 2011;13:898-909. ©2011 Wiley Periodicals, Inc. This meta-analysis compares health care resource use costs, adherence, and persistence between groups of patients taking antihypertensives as single-pill combinations (SPCs) vs free-equivalent components (FEC) based on a structured review of published studies. The search yielded 12 retrospective database studies included in analyses. The mean difference in combined total annual all-cause and hypertension-related (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 J Clin Hypertens (Greenwich). 2011;13:873-880. ©2011 Wiley Periodicals, Inc. This 12-week, multicenter, randomized, double-blinded, 4-arm study in 440 patients with moderate to severe hypertension compared ambulatory blood pressure (ABP) responses with a triple-combination regimen (olmesartan medoxomil [OM] 40?mg, amlodipine besylate [AML] 10?mg, and hydrochlorothiazide [HCTZ] 25?mg) and its component dual-combination regimens at similar doses. At week 12, the triple combination (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=105 United States Patent: 8071763 |-| Title: Methods for treatment of nocturia |-| Inventors: Araki; Tohru (Okayama, JP) |-| Assignee: Daiichi Sankyo Company, Limited (Tokyo, JP) |-| A method for the treatment of nocturia which consists of administering to a mammal in need of such treatment a therapeutically effective amount of a nonsteroidal anti-inflammatory drug consisting of loxoprofen or a pharmacologically acceptable salt thereof, wherein the mammal is a human who has a neurogenic bladder. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=105 United States Patent: 8071649 |-| Title: Method for treatment of nocturia |-| Inventors: Araki; Tohru (Okayama, JP) |-| Assignee: Daiichi Sankyo Company, Limited (Tokyo, JP) |-| A method for treatment of nocturia by administering to a mammal, such as a human, in need of such treatment, a therapeutically effective amount of loxoprofen or a pharmacologically acceptable salt thereof. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=105 United States Patent: 8071300 |-| Title: Drug-phosphorylating enzyme |-| Inventors: Nara; Futoshi (Chiba, JP), Yonesu; Kiyoaki (Tokyo, JP), Kubota; Kazuishi (Kanagawa, JP) |-| Assignee: Daiichi Sankyo Company, Limited (Tokyo, JP) |-| The objects of the present invention are: elucidation of an enzyme that phosphorylates in vivo a compound such as (2R)-2-amino-2-methyl-4-[5-(5-phenylpentanoyl)thiophen-2-yl]butan-1-ol and provision of a method of phosphorylating the aforementioned compound; (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 AIMS/HYPOTHESIS: The primary aim of this completed multicentre randomised, parallel, double-blind placebo-controlled study was to elucidate the mechanisms of glucose-lowering with colesevelam and secondarily to investigate its effects on lipid metabolism (hepatic de novo lipogenesis, cholesterol and bile acid synthesis). METHODS: Participants with type 2 diabetes (HbA(1c) 6.7-10.0% [50-86 mmol/mol], fasting (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 The surface of amorphous compounds crystallizes faster compared to the bulk. This suggests that molecules at the surface have high molecular mobility. Crystallization behavior is affected by various factors including molecular weight and glass transition temperature (T(g). In this study, we focus on troglitazone which is composed of diastereomers, RR/SS and RS/SR, as model compound, because each diastereomer has the same molecular weight and similar chemical structure. Troglitazone is (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 Fingolimod (FTY720) is a sphingosine 1-phosphate receptor (S1PR) modulator currently being evaluated for the treatment of multiple sclerosis. Fingolimod undergoes phosphorylation in vivo to yield fingolimod phosphate (fingolimod-P), which modulates S1PRs expressed on lymphocytes and cells in the central nervous system. The authors developed a population model, using pooled data from 7 phase 1 studies, to enable characterization of fingolimod-P pharmacokinetics following oral administration of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 Olmesartan medoxomil (OM) is a prodrug type angiotensin II type 1 receptor antagonist. The OM-hydrolyzing enzyme responsible for the prodrug bioactivation, was purified from human plasma by successive column chromatography and was molecularly identified by N-Terminal amino acid sequencing, resulting in the identical sequence of 20 amino acids to that of human paraoxonase 1 (PON1). Two recombinant allozymes of human PON1 (PON1(192QQ) and PON1(192RR) were constructed and clearly demonstrated (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=105 BERKELEY, Calif.-(BUSINESS WIRE)- Plexxikon Inc., a member of Daiichi Sankyo Group, today announced scientific findings from two key programs in its oncology pipeline. First, findings from preclinical studies showed that treatment with a novel oral agent, PLX3397, re-programmed the tumor microenvironment, supporting further development of this single agent treatment for certain cancers and malignancies such as prostate cancer. In another presentation, Plexxikon researchers characterized the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=105 NEW YORK-(BUSINESS WIRE)- Deutsche Bank today announced its appointment as depositary bank for the Level I American Depositary Receipt (ADR) program of Japan-based Daiichi Sankyo Company, Ltd. (Daiichi Sankyo). Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. Daiichi Sankyo does business in nearly 60 countries around the world, with world headquarters (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=105 ScienceDaily (Nov. 9, 2011) The relationship of platelet responsiveness to antiplatelet medications; and, the correlation of poor response, and overall platelet aggregation while on dual antiplatelet therapy to the risk of drug-eluting stent thrombosis after 30 days was examined in ADAPT-DES, the largest registry to date to fully examine these relationships. See Also: Health & Medicine Stroke Prevention Heart Disease Blood Clots Personalized Medicine Today's Healthcare Allergy Reference COX-2 (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=105 ScienceDaily (Nov. 9, 2011) A clinical trial comparing prasugrel to clopidogrel for patients with high on-clopidogrel platelet reactivity (HCPR) following percutaneous coronary intervention (PCI) was ended early due to relatively few occurrences of cardiac death or myocardial infarction - the primary endpoint - at six month follow up. See Also: Health & Medicine Stroke Prevention Heart Disease Wounds and Healing Multiple Sclerosis Research Today's Healthcare Pharmacology Reference COX-2 (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=105 ScienceDaily (Nov. 9, 2011) Data from the BRIDGE clinical trial demonstrate that intravenous use of the drug cangrelor was effective at maintaining platelet inhibition in patients on thienopyridines who required bypass surgery. Trial results were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. See Also: Health & Medicine Heart Disease Today's Healthcare Wounds and Healing Pharmacology Skin (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=105 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/0db780/the_pricing_and_re) has announced the addition of Decision Resources, Inc.'s new report "The Pricing and Reimbursement Environment for Respiratory Disease Therapies" to their offering. The Pricing and Reimbursement Environment for Respiratory Disease Therapies Common respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) make up a large and varied pharmaceutical market (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=105 WOBURN, Mass. & TOKYO-(BUSINESS WIRE)-ArQule, Inc. (NASDAQ: ARQL) and Daiichi Sankyo, Co. Ltd. (TSE 4568) announced today the execution of a license agreement for the development of a new AKT inhibitor called ARQ 092, the first compound to emerge from the companies November 2008 agreement to collaborate on research utilizing the AKIP ¢ (ArQule Kinase Inhibitor Platform) technology to generate novel, selective and potent small molecule kinase inhibitors. Under the license agreement, Daiichi (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=105 WOBURN, Mass.-(BUSINESS WIRE)-ArQule, Inc. (NASDAQ: ARQL) today reported its results of operations for the fiscal quarter and nine months ended September 30, 2011. Our oncology drug discovery collaboration with Daiichi Sankyo has reached an important milestone with the decision announced today to license ARQ 092, an inhibitor of the AKT protein kinase The Company reported a net loss of $2,260,000 or $0.04 per share for the quarter ended September 30, 2011, compared to a net loss of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=105 DUBLIN-(BUSINESS WIRE)-Research and Markets(http:/www.researchandmarkets.com/research/738551/nonsmall_cell_lun) has announced the addition of GlobalData's new report "Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering. Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 This report is an essential source of information and analysis on the global Non - Small Cell Lung Cancer (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=105 WOBURN, Mass. & TOKYO-(BUSINESS WIRE)-ArQule, Inc. (NASDAQ: ARQL) and Daiichi Sankyo, Co. Ltd. (TSE 4568) announced today the execution of a license agreement for the development of a new AKT inhibitor called ARQ 092, the first compound to emerge from the companies November 2008 agreement to collaborate on research utilizing the AKIP ¢ (ArQule Kinase Inhibitor Platform) technology to generate novel, selective and potent small molecule kinase inhibitors. Under the license agreement, Daiichi (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=105 BOTHELL, Wash. & CAMBRIDGE, Mass.-(BUSINESS WIRE)-Seattle Genetics, Inc. (NASDAQ:SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502), today announced that ADCETRIS ¢ (brentuximab vedotin) will be featured in multiple presentations at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13, 2011, in San Diego, Calif. The presentations will include data from additional analyses (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=105 DUBLIN-(BUSINESS WIRE)-Research and Markets(http:/www.researchandmarkets.com/research/6b0030/diabetic_nephropat) has announced the addition of Global Markets Direct's new report "Diabetic Nephropathy - Pipeline Review, H2 2011" to their offering. Diabetic Nephropathy - Pipeline Review, H2 2011 Global Markets Direct's, 'Diabetic Nephropathy - Pipeline Review, H2 2011', provides an overview of the Diabetic Nephropathy therapeutic pipeline. This report provides information on the therapeutic (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=105 LUND, Sweden-(BUSINESS WIRE)-BioInvent International AB (STO:BINV) will hold its first Capital Markets Day for investors, analysts and media today. The event will be hosted by Svein Mathisen, CEO, and Sten Westerberg, VP IR of BioInvent. They will be supported by members of the senior team, including Steven Glazer MD, Senior Vice President, Development, Martin Wiles, Senior Vice President, Business Development, Björn Frendéus, Vice President, Preclinical Research and Kristina Berggren, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=105 BOTHELL, Wash.-(BUSINESS WIRE)-Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. Credit Suisse Healthcare ConferenceWednesday, November 9, 2011 at 11:30 a.m. Mountain time in Phoenix, AZ Lazard Capital Markets 8th Annual Healthcare ConferenceTuesday, November 15, 2011 at 11:00 a.m. Eastern time in New York, NY The presentations will be webcast live and available for replay from Seattle Genetics website at (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=105 J Clin Hypertens (Greenwich). 2011;13:801-812. ©2011 Wiley Periodicals, Inc. The authors examined the comparative effectiveness of 4 angiotensin receptor blockers (ARBs) in patients with hypertension using a large electronic medical record database. Analysis of covariance and logistic multivariate regression models were used to estimate the blood pressure (BP) outcomes of 73,012 patients during 13?months of treatment with olmesartan, losartan, valsartan, and irbesartan. Results were (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=105 BOTHELL, Wash.-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2011. The company also highlighted the ADCETRIS (brentuximab vedotin) product launch, recent product development activities and upcoming milestones. The approval of ADCETRIS during the third quarter marked a transformative milestone for Seattle Genetics and our goal of bringing innovative new drugs to cancer patients in need œThe (…)